Peter D. Haytaian - 01 Mar 2024 Form 4 Insider Report for Elevance Health, Inc. (ELV)

Role
EVP & Pres Carelon & CarelonRx
Signature
/s/ Kathleen S. Kiefer, Attorney in fact
Issuer symbol
ELV
Transactions as of
01 Mar 2024
Net transactions value
-$10,199,908
Form type
4
Filing time
05 Mar 2024, 16:24:39 UTC
Previous filing
03 Nov 2023
Next filing
05 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELV Common Stock Tax liability $2,153,161 -4,314 -24% $499.11 13,425 01 Mar 2024 Direct F1
transaction ELV Common Stock Award $0 +2,405 +18% $0.000000 15,830 01 Mar 2024 Direct F2
transaction ELV Common Stock Award $0 +9,152 +58% $0.000000 24,982 01 Mar 2024 Direct F3
transaction ELV Common Stock Options Exercise $2,504,550 +15,000 +60% $166.97* 39,982 04 Mar 2024 Direct
transaction ELV Common Stock Sale $2,103,757 -4,206 -11% $500.18 35,776 04 Mar 2024 Direct F4, F5
transaction ELV Common Stock Sale $944,840 -1,889 -5.3% $500.18 33,887 04 Mar 2024 Direct F4, F5
transaction ELV Common Stock Sale $7,502,700 -15,000 -44% $500.18 18,887 04 Mar 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELV Employee Stock Option (Right to Buy) Award $0 +9,280 $0.000000 9,280 01 Mar 2024 Common Stock 9,280 $499.11 Direct F6
transaction ELV Employee Stock Option (Right to Buy) Options Exercise $0 -15,000 -75% $0.000000 4,908 04 Mar 2024 Common Stock 15,000 $166.97 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
F2 Represents restricted share units. Restrictions lapse as follows:801 shares on 3/1/2025, and 802 shares each on 3/1/2026 and 3/1/2027.
F3 Represents performance based restricted share units. Restrictions lapse on 3/1/2024.
F4 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2023.
F5 This transaction was executed in multiple trades, each at the same price of $500.18. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares at which the transaction was effected.
F6 The option represents a right to purchase a total of 9,280 shares, and is exercisable in two installments of 3,093 shares each, and one installment of 3,094 shares, beginning on 3/1/2025, which is the one-year anniversary of the option grant date.
F7 The option represents a right to purchase a total of 19,908 shares and is exercisable in six semi-annual installments of 3,318 shares each beginning on 9/1/2017, which is the six-month anniversary of the date on which the option was granted.